SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rise is being tied mainly to Morgan Stanley naming it a top pick, with traders highlighting AWS growth and AI opportunities such as Trainium, Bedrock and agentic commerce. Many are bullish on the rally, while others question whether it will last and point to heavy AI spending and uncertain returns as risks.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep slide toward fresh lows, with bearish traders citing possible continued dilution, upcoming filings, and doubts about Truth Socials engagement and business prospects. Political backlash over Trumps policies and midterm prospects dominates the broader debate, while some traders view the decline as a buying opportunity.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

OCUL is drawing attention amid a sharp selloff as competing wet-AMD trial results shake confidence in retinal TKI therapies and raise questions about AXPAXLIs differentiation and commercial prospects. Traders disagree on whether competitor setbacks and Oculars positive SOL-1 results strengthen its position or whether lingering clinical and regulatory uncertainty outweighs its planned NDA filing.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is under pressure amid repeated analyst price-target cuts tied to soft residential roofing demand, a prolonged housing recovery, and higher costs, extending a steep slide toward new lows. Traders are divided between frustration over the selloff and managements limited communication, and long-term optimism about the acquisition strategy and eventual integration gains.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met both co-primary and all secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, addressing the FDAs earlier efficacy concerns; the company plans to resubmit its application. Traders are broadly positive on the results but debate the remaining regulatory path and dizziness reports, while others point to profit-taking and possible short-covering as the stock trades volatile.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent insider share purchases by the CEO and directors have fueled hopes of a rebound, with traders watching for a sustained move above a key technical level. Skeptics point to weakness in the core Celsius brand and say speculation about a Pepsi buyout is unconfirmed.

AXT, Inc. engages in the design, development, manufacture and distribution of compound and single element semiconductor substrates. It also sells specialty material substrates and raw materials used to make substrates and other related products. The company was founded by Morris S. Young and Davis Zhang in 1986 and is headquartered in Fremont, CA.

AXT Inc

AXTI is drawing attention after an earnings-driven rally, with traders pointing to a return to profitability and strong year-over-year revenue growth amid demand for InP substrates used in AI data-center optics. Bulls see room for growth, while skeptics argue the valuation is stretched and the stock remains highly volatile.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and repeated underperformance versus Bitcoin are driving attention, with traders pointing to doubts about its AI/data-center pivot and the lack of signed tenant leases alongside criticism of management and shareholder dilution. Some are buying the sharp dip or anticipating a short squeeze, but bearish traders see continued downside absent a contract or stronger Bitcoin-linked gains.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

XERSs sharp rally and breakout above its prior high are fueling takeover speculation, especially chatter about Lundbeck and a possible bidding war, though no deal is confirmed and some traders doubt the rumors. Others point to revenue growth and the XP-8121 pipeline as support for the companys prospects independent of a sale.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is drawing attention ahead of its quarterly results, with traders focused on margins and profitability despite strong deliveries; bullish bets on the recent rally and an earnings move contrast with bearish expectations of a miss. The Roadster reveal has also fueled speculative SpaceX-merger chatter, though traders disagree about its business significance and whether a deal is likely.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape

AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034   New York, NY – October 15, 2026 – Artificial intelligence is starting to change the way healthcare works, and the opportunity is getting harder to ignore. From spotting diseases […]
The post The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape appeared first on Financial News Media.

VEEV Expands IQVIA Partnership With Clinical Operations Software Suite

Veeva expands its IQVIA partnership with clinical operations software, boosting its market reach and growth prospects through wider adoption and integrated workflows.

IQVIA Selects Veeva Clinical Operations Applications

IQVIA (NYSE:IQV) and Veeva Systems (NYSE: VEEV) today announced an expansion of their partnership with the selection of Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications that will be used across IQVIA clinical development studies. This extends the previously...

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes. IQVIA Life Science Models...

IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Explorer to help customers make better-informed commercial decisions. IQVIA Explorer turns...

Extensive Database & Solid Bookings Benefit IQVIA Amid Low Liquidity

IQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.

IQVIA Holdings Now #239 Largest Company, Surpassing Vivmark Residential

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, IQVIA Holdings Inc (Symbol: IQV) has taken over the #239 spot from Vivmark Residential (Symbol: VMRK), according to The Online Investor.

 Market capitalization is an i...

IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026

IQVIA Holdings Inc. (IQVIA) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2026 financial results before the market opens on Tuesday, October 27...

IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know

IQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission-critical information, technology solutions, and real-world evidence services to the company's life sciences clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial-related services. The Contract Sales and Medical Solutions segment offers healthcare provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1950 and is headquartered in Durham, NC.

IQVIA Holdings Inc

Retail Raves About IQVIA Holdings After Firm Raises Revenue, Profit Guidance

Equity

Bearish Sentiment

IQVIA Holdings Inc, on Monday, reported an upbeat set of earnings that topped Wall Street estimates while also raising its revenue and earnings per share (EPS) guidance for 2024. Following the announcement, shares of the firm jumped nearly 7% and retail sentiment entered extremely bullish territory (76/100) from a neutral zone supported by extremely high message volumes.<figure class="image"><img style="aspect-ratio:795/228;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_22_at_3_09_52_PM_e9a57ca2e1.png" alt="Retail sentiment trends in extremely bullish territory for IQVIA Holdings" width="795" height="228"><figcaption>Retail sentiment trends in extremely bullish territory for IQVIA Holdings</figcaption></figure>The firm, which provides advanced analytics, technology solutions, and clinical research services to the life sciences industry, reported a 2.30% year-over-year (YoY) rise in its second quarter revenue at $3.81 billion which stood higher than a Street estimate of $3.79 billion. Net income rose 22% YoY to $363 million during the quarter. The firm reported an adjusted diluted EPS of $2.64 as compared to a Street estimate of $2.57.IQVIA Holdings pointed out that as of June 30, 2024, Research &amp; Development Solutions (R&amp;DS) contracted backlog (including reimbursed expenses), stood at $30.60 billion–growing 7.70% year-over-year and 8.10% at constant currency. The company said it expects approximately $7.80 billion of this backlog to convert to revenue in the next twelve months.Ari Bousbib, chairman and CEO of IQVIA said the firm delivered second quarter results at the high-end of its guidance, driven mainly by better-than-expected Technology &amp; Analytics Solutions (TAS) performance. TAS revenue came in at $1.49 billion, registering an increase of 2.70% on a reported basis and 3.80% on a constant currency basis.The company has updated its full-year 2024 guidance for revenue to be between $15.43 billion and $15.53 billion, as compared to an earlier guidance of $15.33-15.58 billion. Adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) is expected between $3.71 billion and $3.77 billion, compared with an earlier guidance of $3.70-3.80. Adjusted diluted EPS is estimated between $11.10 and $11.30 compared with an earlier guidance of $10.95-11.25.One Stocktwits user named ‘Wigglyick’ has expressed optimism on the technical pattern formed by the stock, which other users cited as evidence of its improving fundamental picture.<figure class="image"><a href="https://stocktwits.com/Wigglyick"><img style="aspect-ratio:784/612;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_22_at_3_11_34_PM_d36f6ac6b2.png" alt="Stocktwits user Wigglyick's post on IQVIA Holdings" width="784" height="612"></a><figcaption>Stocktwits user Wigglyick's post on IQVIA Holdings</figcaption></figure> &nbsp;

IQVIA Holdings has updated its full-year 2024 guidance for revenue to be between $15.43 billion and $15.53 billion, as compared to an earlier guidance of $15.33-$15.58 billion. 

IQVIA Holdings has updated its full-year 2024 guidance for revenue to be between $15.43 billion and $15.53 billion, as compared to an earlier guidance of $15.33-$15.58 billion. Retail sentiment entered extremely bullish territory (77/100) from a neutral zone supported by extremely high message volumes.

First Trust Exchange-Traded Fund II - First Trust Nasdaq Lux Digital Health Solutions ETF

First Trust Exchange-Traded Fund III - First Trust Health Care AlphaDEX Fund

Invesco Bloomberg Pricing Power ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Mid-Cap Growth ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$264.87
Prev Close	$266.90
Open	$267.52
Dividend Yield	0.00%
50-Day Moving Average	$260.02
Beta	1.05
Avg. Volume	1.61M
PE Ratio	33.11

52-Week High	$277.40
52-Week Low	$154.50
Market Capitalization	$43.93B
EPS (Annual)	$7.84
Price to Book	7.12
Revenue Per Employee	$175,311.83

Feed

News

Sentiment

Earnings

Fundamentals

Info

IQV Fundamentals